Celebrex Articles
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Global pain management drugs market to see moderate growth as generic share continues to rise
24 November 2011
Pfizer COX-2 inhibitor celecoxib has both beneficial and harmful effects, researchers note
15 September 2011
The “new” Pfizer sees 4th qtr s2009 sales and profit rocket, but 2010 guidance disappoints
4 February 2010
Kinaxo discovers new target for Pfizer's Celebrex
30 April 2009
Data on withdrawn drugs was faked; says hospital
16 March 2009
Astellas' revenue up 2% in first half of year
8 December 2008
NicOx shares up 44% on strong late-stage data
10 November 2008
US FTC closes, freezes assets of vast drug spam e-mail network
27 October 2008
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
Astellas looking to overtake Takeda's leading share of home market with newer products
15 September 2008
Pfizer moves to keep market share in Japan
24 March 2008
Array shares jump 17% on Ph II ARRY-797 data
10 March 2008
Pfizer sees 4th-qtr 2007 profits decline, but still beats forecasts; revenue rises 4%
28 January 2008
Favorable ruling in NY state court for Pfizer in Celebrex case
14 January 2008
SCOT trial to compare Celebrex' safety with that of older NSAIDs
24 December 2007
Novartis' Prexige withdrawn by UK, German and Austrian regulators on liver safety fears
26 November 2007
Pfizer
23 July 2007
Japan stock market week to June 18, 2007
25 June 2007
Astellas and Pfizer to sell Celecox in Japan
25 June 2007
Pfizer's Celebrex gets UK OK for AS
7 May 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
Pfizer defends US Celebrex patents from Teva
26 March 2007
Japan stock market week to March 12, 2007
19 March 2007
Pfizer's celecoxib to become Japan's first COX-2 inhibitor
30 October 2006
Japan stock market week to Oct 23, 2006
30 October 2006
Pfizer
31 July 2006
Avicena initiates Ph II trial of ALS drug
17 July 2006
Abraxis to buy Puerto Rico unit from Pfizer
1 May 2006
Celebrex shows efficacy in colon cancer studies
10 April 2006
Study links Pfizer's painkiller Celebrex to an increased risk of myocardial infarction
13 March 2006
Danger to patients from weak US Rx system: CU
12 December 2005
Pfizer Germany sees 2006 recovery
12 September 2005
USA
22 August 2005
Japan stock market week to July 11
18 July 2005
Stock Commentary - Tokyo
18 July 2005
Glimmer of hope for Merck & Co's Vioxx
18 July 2005
Pfizer's Celebrex gains from Bextra withdrawal
30 May 2005
US $4.5B DTC industry faces uncertain future
27 April 2005
Positive data for Endo's Lidoderm patch in OA
11 April 2005
US FDA "heads-up" on new Rx ad guidelines
14 March 2005
Americans understand Rx risk/benefits: study
14 March 2005
Evidence for CV risks of COX-2s; NEJM report
28 February 2005
Stock Commentary - New York
28 February 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
Stock Commentary - New York
14 February 2005
Stock Commentary - New York
31 January 2005
Pfizer agrees to Onsenal launch delay
31 January 2005
US FDA is urged to take Pfizer COX-2s off market
31 January 2005
Vioxx could be cause of 140,000 heart attacks in the USA
31 January 2005
FDA says Pfizer's Celebrex/Bextra ads mislead
24 January 2005
Japan stock market three weeks to January 3
10 January 2005
HIV/AIDS group urges ban on US DTC ads
10 January 2005
UK Ministry advice on COX-2s
10 January 2005
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
